Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.

Ettingshausen, Carmen Escuriola; Hermans, Cedric; Holme, Pål A; Cid, Ana R; Khair, Kate; Oldenburg, Johannes; Négrier, Claude; Botha, Jaco; Lelli, Aurelia; Windyga, Jerzy

Ettingshausen, Carmen Escuriola; Hermans, Cedric; Holme, Pål A; Cid, Ana R; Khair, Kate; Oldenburg, Johannes; Négrier, Claude; Botha, Jaco; Lelli, Aurelia; Windyga, Jerzy.

Afiliação

Ettingshausen CE; Hämophilie-Zentrum Rhein Main - HZRM GmbH, Mörfelden-Walldorf, Germany.
Hermans C; Hemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
Holme PA; Department of Haematology, Oslo University Hospital and Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Cid AR; Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, València, Spain.
Khair K; Centre for Outcomes and Experience Research in Children's Health, Illness and Disability (ORCHID), Great Ormond Street Hospital for Children, London, UK.
Oldenburg J; Institute of Experimental Hematology and Transfusion Medicine, Bonn University Clinic, Bonn, Germany.
Négrier C; University Claude Bernard Lyon 1, Lyon, France.
Botha J; Takeda Pharmaceuticals International AG, Zürich, Switzerland.
Lelli A; Takeda Pharmaceuticals International AG, Zürich, Switzerland.
Windyga J; R&D, Plasma Derived Therapy, Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark-Opfikon, Zürich, Switzerland.